Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding phase 2b study of remibrutinib in chronic spontaneous urticaria inadequately controlled by H1-antihistamines
2018-000993-31Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of remibrutinib in chronic idiopathic urticaria (CIU) (3 arms), sponsored by Novartis. Primary endpoint: Change from baseline in weekly Urticaria Activity Score (UAS7) at Week 4. Started Feb 2019; status: completed.
02
Drugs
remibrutinib
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2018-000993-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000993-31.